PASSAGE BIO, INC. Payments to Acquire Marketable Securities
PASSAGE BIO, INC. (PASG) reported Payments to Acquire Marketable Securities of $88.17 million for the 12-month period ending 2024-12-31, per its S-4/A filed 2026-09-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-09-03
- PASSAGE BIO, INC. payments to acquire marketable securities for the quarter ending 2024-12-31 was $15.58M, a 43.96% decline year-over-year.
- PASSAGE BIO, INC. payments to acquire marketable securities for the quarter ending 2024-09-30 was $21.77M, a 22.56% decline year-over-year.
- PASSAGE BIO, INC. payments to acquire marketable securities for the quarter ending 2024-06-30 was $37.02M, a 67.25% increase year-over-year.
- PASSAGE BIO, INC. payments to acquire marketable securities for the quarter ending 2024-03-31 was $13.81M, a 73.13% decline year-over-year.
- PASSAGE BIO, INC. payments to acquire marketable securities for fiscal 2023 was $129.43M, a 18.00% decline from fiscal 2022.
- PASSAGE BIO, INC. payments to acquire marketable securities for fiscal 2022 was $157.84M, a 22.07% decline from fiscal 2021.
- PASSAGE BIO, INC. payments to acquire marketable securities for fiscal 2021 was $202.55M, a 23.87% decline from fiscal 2020.
- PASSAGE BIO, INC. payments to acquire marketable securities for fiscal 2020 was $266.06M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $15.58M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $37.34M derived: sum of 2 quarters · filed 2026-09-03 | $74.36M derived: sum of 3 quarters · filed 2026-09-03 | $88.17M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $21.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $58.78M derived: sum of 2 quarters · filed 2025-11-10 | $72.59M 10-Q · filed 2025-11-10 | $100.39M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $37.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $50.83M 10-Q · filed 2025-08-12 | $78.62M derived: sum of 3 quarters · filed 2025-08-12 | $106.73M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $13.81M 10-Q · filed 2025-05-13 | $41.60M derived: sum of 2 quarters · filed 2025-05-13 | $69.71M derived: sum of 3 quarters · filed 2025-05-13 | $91.84M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $27.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $55.90M derived: sum of 2 quarters · filed 2025-03-04 | $78.04M derived: sum of 3 quarters · filed 2025-03-04 | $129.43M 10-K · filed 2025-03-04 |
| 2023-09-30 | $28.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $50.24M derived: sum of 2 quarters · filed 2024-11-13 | $101.64M 10-Q · filed 2024-11-13 | $143.17M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $22.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $73.53M 10-Q · filed 2024-08-08 | $115.06M derived: sum of 3 quarters · filed 2024-08-08 | $172.49M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $51.40M 10-Q · filed 2024-05-14 | $92.93M derived: sum of 2 quarters · filed 2024-05-14 | $150.35M derived: sum of 3 quarters · filed 2024-05-14 | $171.83M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $41.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $98.96M derived: sum of 2 quarters · filed 2024-03-04 | $120.43M derived: sum of 3 quarters · filed 2024-03-04 | $157.84M 10-K · filed 2024-03-04 |
| 2022-09-30 | $57.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $78.90M derived: sum of 2 quarters · filed 2023-11-13 | $116.30M 10-Q · filed 2023-11-13 | $148.99M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $21.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $58.88M 10-Q · filed 2023-08-07 | $91.56M derived: sum of 3 quarters · filed 2023-08-07 | $129.27M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $37.40M 10-Q · filed 2023-05-11 | $70.09M derived: sum of 2 quarters · filed 2023-05-11 | $107.80M derived: sum of 3 quarters · filed 2023-05-11 | $179.62M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $32.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $70.40M derived: sum of 2 quarters · filed 2023-03-06 | $142.22M derived: sum of 3 quarters · filed 2023-03-06 | $202.55M 10-K · filed 2023-03-06 |
| 2021-09-30 | $37.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $109.53M derived: sum of 2 quarters · filed 2022-11-10 | $169.86M 10-Q · filed 2022-11-10 | $300.70M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $71.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $132.15M 10-Q · filed 2022-08-04 | $262.99M derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | $60.33M 10-Q · filed 2022-05-16 | $191.16M derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $130.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $266.06M 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $135.22M 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |